Status:
COMPLETED
The Molecular Characterization of Multiple Myeloma at Relapse
Lead Sponsor:
Rigshospitalet, Denmark
Collaborating Sponsors:
Herlev Hospital
Zealand University Hospital
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
Observational study investigating prognostic factors in newly diagnosed and relapsed multiple myeloma patients by use of clinical data, biochemical markers (blood samples), cytogenetic markers and gen...
Detailed Description
Multiple myeloma (MM) is an incurable cancer. The disease can often be brought to a halt with chemotherapy which in younger patients is accompanied by stem cell transplantation. But the disease relaps...
Eligibility Criteria
Inclusion
- patients newly diagnosed with multiple myeloma and at the same time eligible for high dose chemotherapy and autologous stem cell transplantation
- patients with multiple myeloma experiencing relapse after high dose chemotherapy and autologous stem cell transplantation
Exclusion
- for newly diagnosed patients: age or comorbidity preventing high dose chemotherapy and autologous stem cell transplantation,
- for all patients: age below 18, physical or psychological incapability to give an informed consent.
Key Trial Info
Start Date :
March 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
134 Patients enrolled
Trial Details
Trial ID
NCT00639054
Start Date
March 1 2008
End Date
December 1 2014
Last Update
January 7 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Multiple Myeloma Research Laboratory, Dept Hematology, Cph Univ Hosp Rigshospitalet
Copenhagen, Capital Region, Denmark, DK-2100